# Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease

Study · id `cardio:ct-nct04595370` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04595370](<https://clinicaltrials.gov/study/NCT04595370>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04595370

Browse, organ or system: Heart; Kidneys; Metabolism  
Browse, condition area: Heart failure; Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 153 participants.

## Technical summary

Registry record NCT04595370. Randomized; quadruple masking; primary purpose treatment. Start 2021-01-26 (actual); primary completion 2023-09-22 (actual). Results posted on 2024-11-19.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 153 participants (enrolled count; ClinicalTrials.gov record NCT04595370, source copy `cardio:ctgov-nct04595370-2024-11-19`, retrieved 2026-10-26)
- Started: 2021-01-26 (actual) (ClinicalTrials.gov record NCT04595370, source copy `cardio:ctgov-nct04595370-2024-11-19`, retrieved 2026-10-26)
- Primary completion: 2023-09-22 (actual) (ClinicalTrials.gov record NCT04595370, source copy `cardio:ctgov-nct04595370-2024-11-19`, retrieved 2026-10-26)
- Completion: 2023-09-22 (actual) (ClinicalTrials.gov record NCT04595370, source copy `cardio:ctgov-nct04595370-2024-11-19`, retrieved 2026-10-26)
- Results first posted: 2024-11-19 (ClinicalTrials.gov record NCT04595370, source copy `cardio:ctgov-nct04595370-2024-11-19`, retrieved 2026-10-26)
- Countries: United States; Belgium; Bulgaria; Canada; Czechia; Denmark; Germany; Hungary; India; Italy; Japan; Lithuania; Poland; Russia; Slovakia; South Korea; Spain; Sweden; Taiwan; Thailand; Türkiye; Ukraine (ClinicalTrials.gov record NCT04595370, source copy `cardio:ctgov-nct04595370-2024-11-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04595370-2024-11-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease
- Acronym: MIRACLE
- Condition: Heart Failure
- Condition: Chronic Kidney Disease
- Intervention (Drug): AZD9977
- Intervention (Drug): Dapagliflozin
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: 78899c04591de25f1b3624cbf62b5ab87526ed54f23ad3c9f1eb918646093c8a
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
